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a b s t r a c t
Streptomyces is a genus of Gram-positive bacteria that grows in various environments, and
its shape resembles ﬁlamentous fungi. The morphological differentiation of Streptomyces
involves the formation of a layer of hyphae that can differentiate into a chain of spores.
The most interesting property of Streptomyces is the ability to produce bioactive secondary
metabolites, such as antifungals, antivirals, antitumorals, anti-hypertensives, immunosup-
pressants, and especially antibiotics. The production of most antibiotics is species speciﬁc,
and these secondary metabolites are important for Streptomyces species in order to compete
with other microorganisms that come in contact, even within the same genre. Despite the
success of the discovery of antibiotics, and advances in the techniques of their production,
infectious diseases still remain the second leading cause of death worldwide, and bacterial
infections cause approximately 17 million deaths annually, affecting mainly children andthe elderly. Self-medication and overuse of antibiotics is another important factor that con-
tributes to resistance, reducing the lifetime of the antibiotic, thus causing the constant need
for research and development of new antibiotics.
© 2012 Elsevier Editora Ltda.Open access under CC BY-NC-ND license.Streptomyces
Streptomyces is a genus of Gram-positive bacteria that grows
in various environments, with a ﬁlamentous form similar
to fungi. The morphological differentiation of Streptomyces
involves the formation of a layer of hyphae that can differ-
entiate into a chain of spores. This process is unique among
Gram-positives, requiring a specialized and coordinated
metabolism. The most interesting property of Streptomyces is
the ability to produce bioactive secondary metabolites such
as antifungals, antivirals, antitumoral, anti-hypertensives,
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Open access under CC BY-NC-ND licenseand mainly antibiotics and immunosuppressives.1–3 Another
characteristic is of the genus is complex multicellular devel-
opment, in which their germinating spores form hyphae, with
multinuclear aerial mycelium, which forms septa at regular
intervals, creating a chain of uninucleated spores.4
When a spore ﬁnds favorable conditions of temperature,
nutrients, and moisture, the germ tube is formed and the
hyphae develops. The aerial hyphae follows, and a stage set
initiates the organization of various processes such as growthAv. Danilo Areosa 690, Distrito Industrial, Manaus, AM, 69075-351,
and cell cycle. Esporogenic cell may contain 50 or more copies
of the chromosome; the order, position, and segregation of
chromosomes during sporulation is linear, which involves at
.
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Table 1 – Streptomyces with their available genome sequence.
Organism GenBank Size % CG Protein Importance References
S. celicolor AL645882.2 9.05Mb 72.0 7.825 Genetic studies Bentley et al.10
S. avermitilis BA000030.3 9.11Mb 70.7 7.583 Antibiotic (Avermictin) Omura et al.1
S. griseus AP009493.1 8.54Mb 72.2 7.138 Antibiotic (Streptomicin) Ohnishi et al.4
S. bingchenggensis CP002047 11,93Mb 70,8 10.023 Antihelmintic (Milbemicin) Wang et al.13
8.746 Phytopathogen Bignell et al.14
Antibiotics and ﬂuorometabolites Barbe et al.15
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Platensimycin2006 S. platensis
Daptomycin2003 S. roseosporus
Linezolid2000 Synthetic
Mupirocin1985 Pseudomonas fluorescens
Ribostamycin1970 S. ribosidificus
Fosfomycin1969 S. fradiae
Trimethoprim1968 Synthetic
Gentamicin1963 Micromonospora purpurea
Fusidic acid1963 Fusidium coccineum
Nalidixic acid1962 Synthetic
Tinidazole1959 Synthetic
Kanamycin1957 S. kanamyceticus
Rifamycin1957 Amycolatopsis mediterranei
Noviobiocin1956 S. niveus
Vancomycin1956 S. orientalis
Cycloserine1955 S. garyphalus
Lincomycin1952 S. lincolnensis
Erithromycin1952 Saccharopolyspora erythraea
Virginiamycin1952 in S. pristinaespiralis S. virginiae
Isoniazid1951 Synthetic
Viomycin1951 S. vinaceus e S. capreolus
Isoniazid1951 Synthetic
Viomycin1951 S. vinaceus e S. capreolus
Nystatin1950 S. noursei
Tetracycline1950 S. aureofaciens
Neomycin1949 S. fradiae
Chloramphenicol1949 S. venezuelae
Polymyxin1947 Bacillus polymyxa
Nitrofurantoin1947 Synthetic
Cephalosporins1945 S. clavuligerus
Bacitracin1945 Bacillus licheniformis
Cephalosporins1945 S. clavuligerus
Streptomycin1944 S. griseus
Penicillin1941 Penicillium chrysogenum
2000
1970
1960
1950
1940
Fig. 1 – Key ﬁndings and dates of antibiotics. Highlights ofS. scabiei FN554889.1 10Mb
S. cattleya NC 016111 8.1Mb
east two systems (ParAB and FtsK), which lead to differentia-
ion and septation of apical cells into chains of spores. Several
ther genes that are essential for the sporulation of aerial
yphae have been reported in S. coelicolor, for example, the
enes whiG, whiH, whiI, whiA, whiB, and whiD. The explana-
ion for the presence of spores in Streptomyces is probably that
hese fragments appeared mycelial under selective pressure,
hich might involve the need to survive outside of plants and
nvertebrates, or in extreme environments.
The ability of the spores to survive in these hostile envi-
onments must have been increased due to the pigment and
roma present in the spores in some species,5 which stimu-
ates cell development and secondary metabolite production.6
nother important point is the tip of the hypha, which is con-
idered to be the most important region where membrane
roteins and lipids may be secreted, especially in the apical
rea of growth.7 In some Streptomyces, secondary metabolism
nd differentiation can be related.8,9 Phylogenetically, Strepto-
yces are a part of Actinobacteria, a group of Gram-positives
hose geneticmaterial (DNA) isGC-rich (70%)when compared
ith other bacteria such as Escherichia coli (50%). The great
mportance given to Streptomyces is partly because these are
mong the most numerous and most versatile soil microor-
anisms, given their large metabolite production rate and
heir biotransformation processes, their capability of degrad-
ng lignocellulose and chitin, and their fundamental role in
iological cycles of organic matter.10 Two species of Strepto-
yces have been particularly well studied: S. griseus, the ﬁrst
treptomyces to be used for industrial production of an antibi-
tic - streptomycin, and S. coelicolor, the most widely used in
enetic studies. Various strainshavebeen sequencedand their
enomes have been mapped (Table 1).
The genome of S. coelicolor, for example, encodes a large
umber of secreted proteins (819), including 60 proteases,
3 chitinases/chitosanases, eight cellulases/endoglucanases,
hree amylases, and two pactato lyases. Streptomyces are also
mportant in the initial decomposition of organic material,
ostly saprophytic species.11
The production of most antibiotics is species speciﬁc, and
hese secondary metabolites are important so the Strepto-
yces spp. can compete with other microorganisms that may
ome in contact, or even within the same genus. Another
mportant process involving the production of antibiotics
s the symbiosis between Streptomyces and plants, as the
ntibiotic protects the plant against pathogens, and plant
xudates allows the development of Streptomyces.12 Data in
he literature suggest that some antibiotics originated as
ignal molecules, which are able to induce changes in the
xpression of some genes that are not related to a stress
esponse.11the Streptomyces.
Antibiotics
Despite the success of the discovery of antibiotics, and
advances in the process of their production, infectious
diseases still remain the second leading cause of death world-
wide, and bacterial infections cause approximately 17 million
deaths annually, affectingmainly children and the elderly. The
history of antibiotics derived from Streptomyces began with the
discovery of streptothricin in 1942, and with the discovery of
streptomycin two years later, scientists intensiﬁed the search
for antibiotics within the genus. Today, 80% of the antibiotics
are sourced from the genus Streptomyces, actinomycetes being
the most important.16 This can be seen in Fig. 1.
Mechanism of action of antibioticsThe molecular basis of this action is well understood and
the main targets are well known. They are classiﬁed by the
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Fig. 2 – Schematic representation of the target and
mechanism of action of certain antibiotics.
are frequent in this environment. Many resistance genesinteraction of antibiotics targeting essential cellular functions,
the fundamental principle to inhibit bacterial growth.17 This is
a complex process that starts with the physical interaction of
the molecule and its speciﬁc targets and involves biochemical,
molecular, and structural changes, acting on multiple cellular
targets such as: 1) DNA replication, 2) RNA synthesis, 3) cell
wall synthesis, and 4) protein synthesis (Fig. 2).
DNA replication
DNA gyrase (topoisomerase) controls the topology of the DNA
by catalyzing the cleavage pattern andDNAbinding. This reac-
tion is important for DNA synthesis and mRNA transcription,
and the complex-quinolone topoisomerase-DNAcleavagepre-
vents replication, leading to death of the bacteria.18–20
Synthesis of RNA
The DNA-dependent RNA polymerase mediates the transcrip-
tion process and is the main regulator of gene expression
in prokaryotes. The enzymatic process is essential for cell
growth, making it an attractive target for antibiotics. One
example is rifamycin, which inhibits the synthesis of RNA by
using a stable connection with high afﬁnity to the -subunit
in the RNA/DNA channel, separating the active site by inhib-
iting the initiation of transcription and blocking the path of
ribonucleotide chain growth.18–20
Cell wall synthesis
The bacterial cell wall consists of peptidoglycan, which helps
maintain the osmotic pressure, conferring ability to sur-
vive in diverse environments. The peptidoglycan biosynthesis
involves three stages: the ﬁrst stage occurs in the cytoplasm,
where low molecular weight precursors are synthesized. In
the second stage, the cell wall synthesis is catalyzed by
membrane-bound enzymes; and in the third stage the antibi-
otic acts by preventing the -lactams and polymerization12;16(5):466–471
of the glycan synthesis of cell wall enzymes, acting on
transpetidades.18–20
Protein synthesis
The translation process of mRNA occurs in three phases:
initiation, elongation, and termination involving cytoplasmic
ribosomes and other components. The ribosome is composed
of two subunits (50S and 30S), which are targets of the main
antibiotic that inhibits protein synthesis. Macrolides act by
blocking the 50S subunit, preventing the formation of the pep-
tide chain: tetracycline in the 30S subunit acts by blocking the
access of the aminoacyl tRNA-ribosome; spectinomycin inter-
feres with the stability of the peptidyl-tRNA binding to the
ribosome; and streptomycin, kanamycin, and gentamicin act
in the 16S rRNA that is part of the 30S ribosome subunit.18–20
Cytoplasmic membrane
The cytoplasmic membrane acts as a diffusion barrier
to water, ions, and nutrients. The transport systems are
composed primarily of lipids, proteins, and lipoproteins. Dap-
tomycin inserts into the cytoplasmic membrane of bacteria in
a calcium-dependent fashion, forming ion channels, trigger-
ing the release of intracellular potassium. Several antibiotics
can cause disruption of the membrane. These agents can
be divided into cationic, anionic, and neutral agents. The
best known compounds are polymyxin B and colistemethate
(polymyxin E). The polymyxins are not widely used because
they are toxic to the kidney and to the nervous system.18–20
The latest antibiotic launched in 2006 by Merck (platen-
simycin) has different mechanism of action from the previous
ones, since it acts by inhibiting the beta-ketoacyl synthases I /
II (FabF / B), which are key enzymes in the production of fatty
acids, necessary for bacterial cell membrane.13
Resistance
According to Nikaido20 100,000 tons of antibiotics are pro-
duced annually, which are used in agriculture, food, and
health. Their use has impacted populations of bacteria, induc-
ing antibiotics resistance. This resistance may be due to
genetic changes such as mutation or acquisition of resis-
tance genes through horizontal transfer, which most often
occurs in organisms of different taxonomy.21,22 Mutations
can cause changes at the site of drug action, hindering the
action of the antibiotic.23 Most of the resistance genes are
in the same cluster as the antibiotic biosynthesis gene.24 In
nature, the main function of antibiotics is to inhibit competi-
tors, which are induced to inactivate these compounds by
chemical modiﬁcation (hydrolysis), and changes in the site
of action and membrane permeability.25 A study carried out
with Streptomyces fromurban soil showed thatmost strains are
resistant to multiple antibiotics, suggesting that these genes
20are located on plasmids (plasmid A), which can be passed by
conjugation to a susceptible strain; these plasmids are stable
and can express the resistance gene.26 The susceptibility to a
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articular antibiotic can be affected by the physiological state
f the bacteria, and the concentration of the antibiotic; this
ay be observed in bioﬁlms through a mechanism known
s persister formation - small subpopulations of bacteria sur-
ive the lethal concentration of antibiotic without any speciﬁc
esistance mechanisms, although this mechanism does not
roduce high-level resistance.27
Microorganisms growing in a bioﬁlm are associated with
hronic and recurrent human infections and are resistant
o antimicrobial agents.28 The spread of resistant strains is
ot only linked to antibiotic use, but also to the migration
f people, who disperse resistant strains among people in
emote communities where the use of antibiotics is very
imited.24 Due to the difﬁculty of obtaining new antibiotics,
he drug industry has made changes to existing antibiotics;
hese semi-synthetics are more efﬁcient and less susceptible
o inactivation by enzymes that cause resistance. This practice
as become the strategy for the current antibiotics used today
nd is known as the second, third, and fourth generation of
ntibiotics.29,30
enome and new antibiotics
ith the availability of genomes from a large number of
athogens, hundreds of genes have been evaluated as tar-
ets for new antibiotics. A gene is recognized as essential
hen the bacterium can not survive while the gene is inac-
ive, and can become a target when a small molecule can
lter its activity.31 Genetic analysis has shown that a gene
ay encode a function that is important in one bacteria but
ot in another.32 167 genes have been determined as essen-
ial for bacterial growth and are potential targets for new
ntibiotics.33,34 GlaxoSmithKline has conducted studies with
he antibiotic GKS299423 acting on topoisomerase II, in order
o prevent the bacteria from developing resistance.35
se
he world’s demand for antibacterials (antibiotics) is steadily
rowing. Since their discovery in the 20th century, antibiotics
ave substantially reduced the threat of infectious diseases.
he use of these “miracle drugs”, combined with improve-
ents in sanitation, housing, food, and the advent of mass
mmunization programs, led to a dramatic drop in deaths from
iseases that were once widespread and often fatal. Over the
ears, antibiotics have saved lives and eased the suffering of
illions. By keeping many serious infectious diseases under
ontrol, these drugs also contributed to the increase in life
xpectancy during the latter part of the 20th century.
The increasing resistance of pathogenic organisms, lead-
ng to severe forms of infection that are difﬁcult to treat,
as further complicated the situation, as in the case of
arbapenem-resistant Klebsiella pneumoniae,36,37 and other
icroorganisms.38 Infections caused by resistant bacteria do
ot respond to treatment, resulting in prolonged illness and
reater risk of death. Treatment failures also lead to long peri-
ds of infectivity with high rates of resistance, which increase
he number of infected people circulating in the community2;16(5):466–471 469
and thus expose the population to the risk of contracting a
multidrug-resistant strain.39
As bacteria become resistant to ﬁrst generation antibiotics,
treatment has to be changed to second or third generation
drugs, which are often much more expensive and sometimes
toxic. For example, the drug needed to treat multi-drug resis-
tant Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella
pneumoniae, and Mycobacterium tuberculosis, can cost 100 times
more than ﬁrst generation drugs used to treat non-resistant
forms.Mostworrisome is that resistance to virtually all antibi-
otics has increased.
Even though the pharmaceutical industry has intensiﬁed
efforts to develop new drugs to replace those in use, current
trends suggest that some infectionswill haveno effective ther-
apies within the next ten years. The use of antibiotics is the
critical factor in the selection of resistance.40,41 Paradoxically,
underuse through lack of access and inadequate treatment
may play a role as important as overuse. For these reasons,
proper use is a priority to prevent the emergence and spread
of bacterial resistance. Patient-related factors are the main
causes of inappropriate use of antibiotics. For example, many
patients believe that new and expensive drugs are more effec-
tive than older drugs.
In addition to causing unnecessary expenditure, this per-
ception encourages the selection of resistance to these new
drugs, as well as to the older drugs in their class.42 Self-
medication with antibiotics is another important factor that
contributes to resistance, because patients may not take ade-
quate amounts of the drug. In many developing countries,
antibiotics are purchased in single doses and taken only until
the patient feels better, which may occur before the bacteria
is eliminated.43
Physicians can be pressured to prescribe antibiotics to
meet patient expectations, even in the absence of appropri-
ate indications, or by manufacturers’ inﬂuence. Some doctors
tend to prescribe antibiotics to cure viral infections, making
them ineffective against other infections. In some cultural
contexts, antibiotics administered by injection are consid-
ered more effective than oral formulations. Hospitals are a
critical component of the problem of antimicrobial resis-
tance worldwide.14,44 The combination of highly susceptible
patients, patients with serious infections, and intense and
prolonged use of antibiotics has resulted in highly resistant
nosocomial infections, which are difﬁcult to control, making
eradication of the pathogen expensive.
In September 2001, the World Health Organization (WHO)
launched the ﬁrst global strategy to combat the serious prob-
lems caused by the emergence and spread of antimicrobial
resistance. Knownas theWHOGlobal Strategy for theContain-
ment of Antimicrobial Resistance,45 the strategy recognizes
that antimicrobial resistance is a global problem that must
be addressed in all countries. No nation, however effective,
can close its border to resistant bacteria, thus proper control
is required in all places. Much of the responsibility lies with
national governments,with a strategy andparticular attention
to interventions that involve the introduction of legislation
and policies governing the development, licensing, distribu-
tion, and sale of antibiotics.46
Finding new antibiotics that are effective against bacte-
rial resistance is not impossible, but it is a complex and
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challenging area of research. It is also anarea that hasnot been
the primary focus of the pharmaceutical industry in recent
years, because antibiotics generally represent a relatively low
return of investment, and the high standards for drug devel-
opment are also factors that inﬂuence this lack of interest.
Despite the expected growth trends for the global market
of antibiotics, their long-term success is primarily inﬂuenced
by two main factors - resistance and generic competition.
Antibiotic resistance forces reduction in use. The increase
in antibiotic resistance makes curing infections difﬁcult. A
major disadvantage is the difﬁculty of the industry to ﬁnd
new antibiotics - those in use are generally ongoing modiﬁ-
cations to produce new forms. Despite the advantages large
companies have in the development of new antibiotics: a)
well-deﬁned targets, b) mode of research effectively estab-
lished, c) biomarkers for monitoring, d) sophisticated tools to
study dosing, and e) faster approval by regulatory agencies,
they have given priority to other diseases, because the return
on investment for antibiotics is low, despite representing a
market of $ 45 billion, second only to drugs for cardiovascu-
lar problems and central nervous system.47 Another problem
is competition from generics at far lower prices.48 In some
cases the large companies have transferred the responsibil-
ity to small businesses to develop new antibiotics, such as
daptomycin, developed by Cubist and licensed to Lilly.49
Perspectives
Despite this scenario, some companies have established a
social position and responsibility to maintain the develop-
ment of new antibiotics. An example is the potential for such
partnerships in the ﬁght against tuberculosis (TB). Today, mul-
tidrug resistant TB affects half amillion people annually, takes
two years to treat, is cured in only half of the cases, and occurs
mainly in areas where the human development index is low.
To accelerate the development of new treatments, an
important collaboration, the TB Alliance, is exploring cre-
ative funding mechanisms and support for the ﬁnal phase of
clinical trials. Another important action is the collection of
microorganisms in different environments, such as marine
environments, for the isolation of new substances; these
studieshave achieved important results evaluating these envi-
ronment actinomycetes.30,50 Another initiative is the Amazon
Biotechnology Center-CBA, that has been studying microor-
ganisms in the Amazon region, since this region, with its
high diversity of microorganisms, has the capacity to produce
new antibiotics; excellent results have been achieved mainly
regarding Mycobacterium tuberculosis.
There is still a need for regulation of the use of antibiotics
to encourage pharmaceutical companies to invest in devel-
oping new antibiotics. The main challenge remains at the
regulatory level, in order to ﬁnd a solution that ensures the
commercial viability of antibiotic development. The merger
of these companies has an immediate impact, reducing the
number of competing research and development groups; such
changes often cause a strategic review of the therapeutic areas
of research and development, where development of new
antibiotics must compete with other areas that may be more
commercially attractive.12;16(5):466–471
In contrast to theﬁrst antibiotic,where themolecularmode
of action was unknown until after it was introduced into
the market, technologies have evolved (functional genomics),
allowing the evaluation of the interaction between themecha-
nism of action of the antibiotic target and the development of
speciﬁc resistance of the bacteria.51,52 Despite the sequencing
projects of pathogenic organisms and the study of new targets,
little success has been achieved.53,54 Froma technical perspec-
tive, companies that remain committed to research into new
antibiotics using the new technologies will be successful; the
challenges are great, but not insurmountable.
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